S2k‐Leitlinie – Chronischer Pruritus

Ständer, Sonja; Darsow, Ulf; Mettang, Thomas; Gieler, Uwe; Maurer, Marcus; Ständer, Hartmut; Beuers, Ulrich; Niemeier, V.; Gollnick, Harald; Vogelgsang, Maria; Weißhaar, Elke

doi:10.1111/j.1610-0387.2012.08005.x

Cited by 57 publications

(88 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Causal and symptomatic therapies result in the most diverse therapeutic options since pruritus has so many causes. In many scenarios, novel therapeutic approaches or special vehicles require magistral formulas [4,5]. The new Pharmacy Practice Act requires a plausibility check of each prescription since 2012, so that frequently individual formulations are scrutinized, so that therapeutic alternatives in the form of magistral formulas are very welcome.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?

Staubach¹,

Metz

2013

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryPruritus is a common symptom encountered by many different specialties. One must clinically differentiate between pruritus associated with skin disease or inflammation and pruritus with normal skin. Searching for possible underlying diseases is indispensable, because pruritus can be very chronic and has multiple pathogenetic mechanisms. Therapy -especially topical therapy -is difficult and often not successful. Very often systemic treatment has to be combined with topical approaches, considering both the active ingredients and appropriate vehicles. There are still open therapeutic gaps in the pharmaceutical product market, which can partially be resolved by using standard prescriptions for formulations. Due to the new pharmacy practice order, standardized compounded formulations should be given preference, since individual formulations often do not pass the plausibility check of the compounding pharmacist. Also the use of cosmetic ingredients (by example, commercial cold creams) is no longer permitted, since only ingredients with pharmaceutical quality can be used in compounding. We will show -based on practical cases -different therapeutic options for treatment with standardized magistral formulations from the NRF (New German Pharmacopoeia for compounded medications). Systemic and topical therapeutic agents complement each other in their efficacy. Causal and symptomatic therapies result in the most diverse therapeutic options since pruritus has so many causes. In many scenarios, novel therapeutic approaches or special vehicles require magistral formulas [4,5]. The new Pharmacy Practice Act requires a plausibility check of each prescription since 2012, so that frequently individual formulations are scrutinized, so that therapeutic alternatives in the form of magistral formulas are very welcome. We will present only established magistral formulas of the NRF that have already undergone a plausibility check [6,7]. Petra

show abstract

Section: Discussionmentioning

confidence: 99%

“…(2) Antihistamines in most cases of chronic pruritus are not sufficiently effective in their normal dosage. The current pruritus guidelines recommend employing higher dosages of antihistamines [4]. (3) Due to the chronic course, new therapeutic options and concepts are always in demand.…”

Section: Indications For Magistral Formulas In Pruritusmentioning

confidence: 99%

Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?

Staubach¹,

Metz

2013

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Aber gerade bei Pruritus gibt es hier deutliche Grenzen: (1) Mit Ausnahme einiger Antihistaminika, welche die Zulassung zur Therapie von Pruritus bei Urtikaria haben, gibt es keine für die Therapie des Pruritus zugelassenen systemischen Therapeutika, (2) Antihistaminika sind in den meisten Fällen bei chronischem Pruritus in einer Einfachdosis nicht ausreichend wirksam. Die aktuellen Pruritus-Leitlinien empfehlen den Einsatz höherer Dosierungen von Antihistaminika [4]. (3) Aufgrund der Chronizität sind neue therapeutische Optionen und Konzepte immer wieder gefordert.…”

Section: Indikation Zur Magistralrezeptur Bei Pruritusunclassified

“…Kausale und symptomatische Therapien führen zu den vielfältigsten therapeutischen Optionen aufgrund der Diversität der Pruritus-Ursachen. Rezepturen können hilfreich sein, da bestimmte Indikationen und Erkrankungen, besondere Merkmale von Inhaltsstoffen sowie Neuerungen im therapeutischen Spektrum Magistralrezepturen erfordern [4,5]. Die neue Apothekenbetriebsordnung fordert seit 2012 eine Plausibilitätsprüfung bei jeder Rezeptur, sodass es häufig zu einer Überprüfung der Individualrezepturen kommt und therapeutische Alternativen in Form von Magistralrezepturen sehr willkommen sind.…”

Section: Indikation Zur Magistralrezeptur Bei Pruritusunclassified

See 1 more Smart Citation

Magistralrezeptur und Pruritustherapie – Was ist etabliert, was hat sich bewährt, was ist neu?

Staubach

Metz

2013

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Pruritus, Prurigo and Lichen Simplex

Ständer

Greaves

2016

Rook's Textbook of Dermatology, Ninth Edition

View full text Add to dashboard Cite

Chronic pruritus (of more than 6 weeks duration) is one of the most frequent and burdensome of symptoms, occurring not only in association with a variety of dermatoses but also in other medical specialities, such as neurology, gynaecology and psychiatry. Prurigo nodularis and lichen simplex are characterized by a vicious circle of repeated scratching and pruritus, and represent cutaneous reaction patterns with a high negative impact on patients' quality of life. During the past two decades, new insights have been gained on specific neurons, receptors and mediators that are exclusively involved in the mediation of pruritus and not of pain. Diagnostic work‐up of chronic pruritus, prurigo nodularis and lichen simplex is challenging and time‐consuming, and management of the conditions remains difficult and unsatisfactory. The mainstays of treatment to date are antihistamines, anticonvulsants and certain antidepressants. Better understanding of the underlying pathophysiology of pruritus has enabled novel treatment approaches that target the pruritus‐specific mechanisms. Current knowledge on treatment is summarized for the first time in the European Guideline on Chronic Pruritis.

show abstract

S2k‐Leitlinie – Chronischer Pruritus

Cited by 57 publications

References 101 publications

Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?

Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?

Magistralrezeptur und Pruritustherapie – Was ist etabliert, was hat sich bewährt, was ist neu?

Pruritus, Prurigo and Lichen Simplex

Contact Info

Product

Resources

About